Ziltivekimab (low-grade evidence), a human monoclonal antibody targeting interleukin-6 (IL-6) ligand, was tested in CKD patients with inflammatory status and was shown to improve the markers of anemia [29], whereas Canakinumab (high-grade evidence), an antibody targeting IL-1β, has also been shown to reduce major CV events in CKD patients and atherosclerosis and, particularly, in those with immediate anti-inflammatory response to this drug [30]. Here, IL6 is linked to chronic kidney disease.